PACB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

41.82M

+6.61%

-0.152

-1620%

41.31M

+11.19%

-0.144

-90%

43.57M

+9.57%

-0.132

-5.71%

Estimates Revision

The market is revising Downward the revenue expectations for Pacific Biosciences of California, Inc. (PACB) for FY2025, with the revenue forecasts being adjusted by -1.84% over the past three months. During the same period, the stock price has changed by 33.33%.

Revenue Estimates for FY2025

Revise Downward

-1.84%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.28%

In Past 3 Month

Stock Price

Go Up

+33.33%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.30 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.50

Averages

2.30

High

3.00

Current: 0.000

Low

1.50

Averages

2.30

High

3.00

Barclays

Luke Sergott

Equal Weight

maintain

2025-12-15

Reason

Barclays

Luke Sergott

Price Target

2025-12-15

maintain

Equal Weight

Reason

Barclays analyst Luke Sergott raised the firm's price target on PacBio to $2 from $1.50 and keeps an Equal Weight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Piper Sandler

Neutral

maintain

2025-11-11

Reason

Piper Sandler

Price Target

2025-11-11

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on PacBio to $2 from $1.50 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.

Stephens

Overweight

maintain

2025-11-10

Reason

Stephens

Price Target

2025-11-10

maintain

Overweight

Reason

Stephens raised the firm's price target on PacBio to $2 from $1.80 and keeps an Overweight rating on the shares. While noting that the company reported Q3 results that missed expectations, the firm thinks expanding Revio utilization has potential to support upside to its consumable estimates and contends that NIH clarity could drive stronger instruments than it models.

Piper Sandler

Neutral

maintain

2025-08-11

Reason

Piper Sandler

Price Target

2025-08-11

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on PacBio to $1.50 from $1.25 following quarterly results. The firm keeps a Neutral rating on the shares.

Bernstein

Eve Burstein

Outperform

maintain

2025-08-08

Reason

Bernstein

Eve Burstein

Price Target

2025-08-08

maintain

Outperform

Reason

Bernstein analyst Eve Burstein raised the firm's price target on PacBio to $1.70 from $1.50 and keeps an Outperform rating on the shares. The firm notes PacBio reported 2Q25 results Thursday, with revenue of $39.8M 9% above consensus estimates of $36.6M. The company narrowed FY25 revenue guidance, but raised the gross margin guide and lowered the OpEx guide, Bernstein adds.

Barclays

Luke Sergott

Equal Weight

downgrade

2025-06-25

Reason

Barclays

Luke Sergott

Price Target

2025-06-25

downgrade

Equal Weight

Reason

Barclays analyst Luke Sergott lowered the firm's price target on PacBio to $1.50 from $2 and keeps an Equal Weight rating on the shares. The shares ran up in early June following upbeat commentary at a conference, which creates a relatively higher bar for second half of 2025 numbers, the analyst tells investors in a research note. This makes Barclays more cautious given the "tough" National Institutes of Health funding environment.

Valuation Metrics

The current forward P/E ratio for Pacific Biosciences of California Inc (PACB.O) is -3.33, compared to its 5-year average forward P/E of -10.08. For a more detailed relative valuation and DCF analysis to assess Pacific Biosciences of California Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.08

Current PE

-3.33

Overvalued PE

0.96

Undervalued PE

-21.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-11.64

Current EV/EBITDA

-7.15

Overvalued EV/EBITDA

-0.82

Undervalued EV/EBITDA

-22.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

14.41

Current PS

3.24

Overvalued PS

28.76

Undervalued PS

0.05

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PACB News & Events

Events Timeline

No data

News

3.5

01-08Globenewswire

PacBio Unveils CiFi Technology for Chromosome-Scale Assemblies in Single Sequencing Run

7.5

2025-12-31Benzinga

ARK Invest Increases Holdings in Gene Editing Firms, PACB Stock Rises

6.0

2025-12-31Yahoo Finance

Pacific Biosciences Raises Price Target to $2, Outlook Positive

People Also Watch

Frequently Asked Questions

What is Pacific Biosciences of California Inc (PACB) stock price today?

The current price of PACB is 2.04 USD — it has decreased -4.23 % in the last trading day.

What is Pacific Biosciences of California Inc (PACB)'s business?

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

What is the price predicton of PACB Stock?

What is Pacific Biosciences of California Inc (PACB)'s revenue for the last quarter?

Pacific Biosciences of California Inc revenue for the last quarter amounts to 38.44M USD, decreased -3.82 % YoY.

What is Pacific Biosciences of California Inc (PACB)'s earnings per share (EPS) for the last quarter?

Pacific Biosciences of California Inc. EPS for the last quarter amounts to -0.13 USD, decreased -40.91 % YoY.

What changes have occurred in the market's expectations for Pacific Biosciences of California Inc (PACB)'s fundamentals?

How many employees does Pacific Biosciences of California Inc (PACB). have?

Pacific Biosciences of California Inc (PACB) has 575 emplpoyees as of January 09 2026.

What is Pacific Biosciences of California Inc (PACB) market cap?

Today PACB has the market capitalization of 615.89M USD.